2026 Q2 - tulosraportti
Vain PDF
50 päivää sitten
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 13 | - | - | ||
| 1 | - | - | ||
| 12 | - | - | ||
| 613 | - | - | ||
| 35 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 - tulosraportti 12.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 13.8. | ||
2026 Q1 - tulosraportti 12.5. | ||
2025 Q4 - tulosraportti 17.2. | ||
2025 Q3 - tulosraportti 11.11.2025 | ||
2025 Q2 - tulosraportti 12.8.2025 |
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·3 päivää sittenMilan 6-8 October Congress/Vienna, 30 September-3 Oct Noticed that an employee (General Manager) from Taisho Pharma gave a thumbs up ahead of the Congress in Milan and Vienna on Moberg's Linkedin. Taisho sells over-the-counter products in Japan. Who knows, maybe some deal in the making at the Congress meeting. Japan and USA left and then they have agreements for the most crucial regions. https://www.taisho.co.jp/en/products/2019: Moberg Pharma signed an exclusive license agreement with Taisho for MOB-015 in Japan. * Taisho would finance development and registration as well as handle marketing, distribution and sales in Japan. * The agreement could provide Moberg with up to 50 million USD in milestone payments, including 5 million USD upon signing of the agreement. * March 2023: Taisho terminated the development of MOB-015 for strategic reasons and Moberg got back all rights in Japan. Moberg got to keep the already paid 5 million USD.
·25.9.Good grief how I look forward to 2026’Q4 and 2027’Q1 where hopefully there is/will be started up in some of the many potential markets. Quite a long wait - but am sure 2027 will be a fantastic equity year for Moberg
My 65.000 MOB shares are tucked so well into the mattress that I will definitely be sleeping soundly on top of them for the coming minimum 5 years - as long as the company does not lose its grip along the way. Just saying ☝️
·23.9.Moberg Pharma AB (OMX: MOB) announces that the sales representatives of the company's local partner Padagis Israel Agencies Ltd. today have initiated the marketing of Terclara® to dermatologists in Israel. The launch follows regulatory clearance from the Israeli Ministry of Health (MOH) for the first commercial batch. Israel is the first market where the drug MOB-015 (Terclara®) is launched outside the Nordics. As in the Nordics, the product is launched under Moberg Pharma's brand Terclara®. "We are very pleased to see Terclara® launched in Israel and to reach yet another important milestone in the international commercialization of our product. Padagis has carried out extensive preparations ahead of the launch and we look forward to supporting them as Terclara® is now introduced on the Israeli market," says Anna Ljung, CEO of Moberg Pharma. For further information, please contact: Anna Ljung, CEO, telephone: +46 8 522 307 01, email: anna.ljung@mobergpharma.se.From an economic perspective, this is not a huge event, which is why the share price is not exactly exploding today. What you can use this announcement for is to be confirmed in whether you believe in the messages the company overall is coming out with regarding rollout plans. This announcement hits the mark, which is positive - the crucial point now is the total EU rollout, 19 countries by the end of this year. Volatility in share price formation may occur by then, in both upward and downward directions, based on the announcements that are still pending - only time will tell☝️
·15.9.upcoming live broadcast on September 23, With Moberg... https://www.redeye.se/events/1148532/investor-forum-online-43?utm_source=eventlive&utm_medium=email&utm_content=view&tab=attendingcompanies
Hope there will be some new info tomorrow, am very interested in how the rollout is going
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tuotteita joiden kohde-etuutena tämä arvopaperi
Välittäjätilasto
Dataa ei löytynyt
2026 Q2 - tulosraportti
Vain PDF
50 päivää sitten
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·3 päivää sittenMilan 6-8 October Congress/Vienna, 30 September-3 Oct Noticed that an employee (General Manager) from Taisho Pharma gave a thumbs up ahead of the Congress in Milan and Vienna on Moberg's Linkedin. Taisho sells over-the-counter products in Japan. Who knows, maybe some deal in the making at the Congress meeting. Japan and USA left and then they have agreements for the most crucial regions. https://www.taisho.co.jp/en/products/2019: Moberg Pharma signed an exclusive license agreement with Taisho for MOB-015 in Japan. * Taisho would finance development and registration as well as handle marketing, distribution and sales in Japan. * The agreement could provide Moberg with up to 50 million USD in milestone payments, including 5 million USD upon signing of the agreement. * March 2023: Taisho terminated the development of MOB-015 for strategic reasons and Moberg got back all rights in Japan. Moberg got to keep the already paid 5 million USD.
- ·25.9.Good grief how I look forward to 2026’Q4 and 2027’Q1 where hopefully there is/will be started up in some of the many potential markets. Quite a long wait - but am sure 2027 will be a fantastic equity year for MobergMy 65.000 MOB shares are tucked so well into the mattress that I will definitely be sleeping soundly on top of them for the coming minimum 5 years - as long as the company does not lose its grip along the way. Just saying ☝️
- ·23.9.Moberg Pharma AB (OMX: MOB) announces that the sales representatives of the company's local partner Padagis Israel Agencies Ltd. today have initiated the marketing of Terclara® to dermatologists in Israel. The launch follows regulatory clearance from the Israeli Ministry of Health (MOH) for the first commercial batch. Israel is the first market where the drug MOB-015 (Terclara®) is launched outside the Nordics. As in the Nordics, the product is launched under Moberg Pharma's brand Terclara®. "We are very pleased to see Terclara® launched in Israel and to reach yet another important milestone in the international commercialization of our product. Padagis has carried out extensive preparations ahead of the launch and we look forward to supporting them as Terclara® is now introduced on the Israeli market," says Anna Ljung, CEO of Moberg Pharma. For further information, please contact: Anna Ljung, CEO, telephone: +46 8 522 307 01, email: anna.ljung@mobergpharma.se.From an economic perspective, this is not a huge event, which is why the share price is not exactly exploding today. What you can use this announcement for is to be confirmed in whether you believe in the messages the company overall is coming out with regarding rollout plans. This announcement hits the mark, which is positive - the crucial point now is the total EU rollout, 19 countries by the end of this year. Volatility in share price formation may occur by then, in both upward and downward directions, based on the announcements that are still pending - only time will tell☝️
- ·15.9.upcoming live broadcast on September 23, With Moberg... https://www.redeye.se/events/1148532/investor-forum-online-43?utm_source=eventlive&utm_medium=email&utm_content=view&tab=attendingcompaniesHope there will be some new info tomorrow, am very interested in how the rollout is going
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 13 | - | - | ||
| 1 | - | - | ||
| 12 | - | - | ||
| 613 | - | - | ||
| 35 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 - tulosraportti 12.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 13.8. | ||
2026 Q1 - tulosraportti 12.5. | ||
2025 Q4 - tulosraportti 17.2. | ||
2025 Q3 - tulosraportti 11.11.2025 | ||
2025 Q2 - tulosraportti 12.8.2025 |
Tuotteita joiden kohde-etuutena tämä arvopaperi
Välittäjätilasto
Dataa ei löytynyt
2026 Q2 - tulosraportti
Vain PDF
50 päivää sitten
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 - tulosraportti 12.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 13.8. | ||
2026 Q1 - tulosraportti 12.5. | ||
2025 Q4 - tulosraportti 17.2. | ||
2025 Q3 - tulosraportti 11.11.2025 | ||
2025 Q2 - tulosraportti 12.8.2025 |
Tuotteita joiden kohde-etuutena tämä arvopaperi
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·3 päivää sittenMilan 6-8 October Congress/Vienna, 30 September-3 Oct Noticed that an employee (General Manager) from Taisho Pharma gave a thumbs up ahead of the Congress in Milan and Vienna on Moberg's Linkedin. Taisho sells over-the-counter products in Japan. Who knows, maybe some deal in the making at the Congress meeting. Japan and USA left and then they have agreements for the most crucial regions. https://www.taisho.co.jp/en/products/2019: Moberg Pharma signed an exclusive license agreement with Taisho for MOB-015 in Japan. * Taisho would finance development and registration as well as handle marketing, distribution and sales in Japan. * The agreement could provide Moberg with up to 50 million USD in milestone payments, including 5 million USD upon signing of the agreement. * March 2023: Taisho terminated the development of MOB-015 for strategic reasons and Moberg got back all rights in Japan. Moberg got to keep the already paid 5 million USD.
- ·25.9.Good grief how I look forward to 2026’Q4 and 2027’Q1 where hopefully there is/will be started up in some of the many potential markets. Quite a long wait - but am sure 2027 will be a fantastic equity year for MobergMy 65.000 MOB shares are tucked so well into the mattress that I will definitely be sleeping soundly on top of them for the coming minimum 5 years - as long as the company does not lose its grip along the way. Just saying ☝️
- ·23.9.Moberg Pharma AB (OMX: MOB) announces that the sales representatives of the company's local partner Padagis Israel Agencies Ltd. today have initiated the marketing of Terclara® to dermatologists in Israel. The launch follows regulatory clearance from the Israeli Ministry of Health (MOH) for the first commercial batch. Israel is the first market where the drug MOB-015 (Terclara®) is launched outside the Nordics. As in the Nordics, the product is launched under Moberg Pharma's brand Terclara®. "We are very pleased to see Terclara® launched in Israel and to reach yet another important milestone in the international commercialization of our product. Padagis has carried out extensive preparations ahead of the launch and we look forward to supporting them as Terclara® is now introduced on the Israeli market," says Anna Ljung, CEO of Moberg Pharma. For further information, please contact: Anna Ljung, CEO, telephone: +46 8 522 307 01, email: anna.ljung@mobergpharma.se.From an economic perspective, this is not a huge event, which is why the share price is not exactly exploding today. What you can use this announcement for is to be confirmed in whether you believe in the messages the company overall is coming out with regarding rollout plans. This announcement hits the mark, which is positive - the crucial point now is the total EU rollout, 19 countries by the end of this year. Volatility in share price formation may occur by then, in both upward and downward directions, based on the announcements that are still pending - only time will tell☝️
- ·15.9.upcoming live broadcast on September 23, With Moberg... https://www.redeye.se/events/1148532/investor-forum-online-43?utm_source=eventlive&utm_medium=email&utm_content=view&tab=attendingcompaniesHope there will be some new info tomorrow, am very interested in how the rollout is going
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 13 | - | - | ||
| 1 | - | - | ||
| 12 | - | - | ||
| 613 | - | - | ||
| 35 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Välittäjätilasto
Dataa ei löytynyt